EGFR and non-small cell lung carcinoma: The discovery of gefitinib, the first generation of EGFR-tyrosine kinase inhibitors (TKIs) paved the way for targeted therapy for NSCLC patients with activating EGFR mutations (L858R and exon-19 deletion).